Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity

Covid19 Clinical Trial

Official title:

Role of Hematological Parameters in the Stratification of COVID-19 Disease Severity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04670328
• Other study ID #: FMHCMD
• Status: Completed
• Start date: May 1, 2020
• Est. completion date: July 31, 2020

Study information

• Verified date: December 2020
• Source: FMH College of Medicine and Dentistry
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity.

Description:

Objective:

COVID-19 virus involves respiratory as well as other body systems including cardiovascular, gastrointestinal, neurological, immunological and hematopoietic system. Patient of covid-19 pneumonia presents with wide range of hemostatic abnormalities. These hemostatic abnormalities in COVID-19 are related with disease progression, severity and mortality. The Objective of our study is to evaluate the role of hematological parameters in determination of COVID-19 disease severity.

Material and Method:

This was a retrospective study, conducted in Department of Pathology and Department of medicine, FMH college of Medicine and Dentistry from May 2020 to July 2020. Total of 101, confirmed cases of covid-19 disease, both genders between 17 to 75-year age were included. Hematological parameters were compared in mild, moderate, severe and critical disease group. Continuous variables were analyzed by using non parametric, Kruskal Wallis test while categorical variables were analyzed by chi-square test.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 101
• Est. completion date: July 31, 2020
• Est. primary completion date: July 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 17 Years to 75 Years

Eligibility

Inclusion Criteria:

• diagnosed cases of covid-19 disease

• Both genders

• 17 to 75 year age

Exclusion Criteria:

• known case of chronic liver disease

• known hematological diseases were excluded

Related Conditions & MeSH terms

• Covid19

Intervention

Diagnostic Test:
• not required
Diagnostic tests( hematological parameters) were assessed.

Locations

Country	Name	City	State
Pakistan	FMH college of medicine and dentistry	Lahore	Punjab

Sponsors (1)

Lead Sponsor	Collaborator
FMH College of Medicine and Dentistry

Country where clinical trial is conducted

Pakistan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	LDH, serum ferritin level	improvement in LDH and were assessed	3 months
Primary	complete blood count- Hemoglobin. White blood count, platelet count, Neutrophil to lymphocyte ratio	disease severity was assessed on basis of hematological parameters.	3 months
Secondary	PT, APTT and D-dimer	improvement in PT, APTT and D-dimer levels were assessed	3 months